Business Description
Novacyt SA
NAICS : 325413
ISIN : FR0010397232
Compare
Compare
Traded in other countries / regions
ALNOV.FranceNYZ.GermanyNCYT.UKNVYTF.USA IPO Date
2012-10-12Description
Novacyt SA is engaged in developing and selling diagnostic products for cancer and infectious diseases. Its diagnostic products are used in LBC, oncology, microbiology, hematology, and serology testing. The company operates its business through the following business segments. Primerdesign is the designer, manufacturer, and marketer of molecular 'real-time' qPCR testing devices and reagents in the areas of infectious diseases based in Southampton, UK: Lab21 Product segment is a developer, manufacturer, and distributor of a large range of protein-based infectious disease IVD products; IT-IS International segment develops PCR devices for the life sciences and food testing industry and Corporate segment.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 99.81 | |||||
| Equity-to-Asset | 0.82 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.07 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 1.85 | |||||
| Beneish M-Score | -1.66 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 5 | |||||
| 3-Year EBITDA Growth Rate | -108.4 | |||||
| 3-Year EPS without NRI Growth Rate | -55.9 | |||||
| 3-Year FCF Growth Rate | -97.2 | |||||
| 3-Year Book Growth Rate | 95 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 40.55 | |||||
| 9-Day RSI | 36.67 | |||||
| 14-Day RSI | 35.25 | |||||
| 6-1 Month Momentum % | -22.66 | |||||
| 12-1 Month Momentum % | -68.02 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.25 | |||||
| Quick Ratio | 5.13 | |||||
| Cash Ratio | 3.59 | |||||
| Days Inventory | 150.07 | |||||
| Days Sales Outstanding | 476.76 | |||||
| Days Payable | 20.46 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.7 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 27.28 | |||||
| Operating Margin % | -78.64 | |||||
| Net Margin % | -121.58 | |||||
| ROE % | -19.64 | |||||
| ROA % | -15.59 | |||||
| ROIC % | -27.8 | |||||
| ROC (Joel Greenblatt) % | -95.6 | |||||
| ROCE % | -14.66 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.35 | |||||
| PB Ratio | 0.25 | |||||
| Price-to-Tangible-Book | 0.27 | |||||
| EV-to-EBIT | 2.92 | |||||
| EV-to-EBITDA | 4.9 | |||||
| EV-to-Revenue | -2.7 | |||||
| EV-to-FCF | 4.05 | |||||
| Price-to-Projected-FCF | 0.14 | |||||
| Price-to-Median-PS-Value | 1.17 | |||||
| Price-to-Net-Current-Asset-Value | 0.28 | |||||
| Price-to-Net-Cash | 0.47 | |||||
| Earnings Yield (Greenblatt) % | 34.25 |
Balance Sheet Breakdown
Cashflow Statement Breakdown
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Novacyt SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 24.443 | ||
| EPS (TTM) (€) | -0.416 | ||
| Beta | -1.85 | ||
| Volatility % | 76.7 | ||
| 14-Day RSI | 35.25 | ||
| 14-Day ATR (€) | 0.026662 | ||
| 20-Day SMA (€) | 0.492955 | ||
| 12-1 Month Momentum % | -68.02 | ||
| 52-Week Range (€) | 0.46 - 2.048 | ||
| Shares Outstanding (Mil) | 70.63 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Novacyt SA Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Novacyt SA Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Novacyt SA Frequently Asked Questions
What is Novacyt SA(XPAR:ALNOV)'s stock price today?
The current price of XPAR:ALNOV is €0.47. The 52 week high of XPAR:ALNOV is €2.05 and 52 week low is €0.46.
When is next earnings date of Novacyt SA(XPAR:ALNOV)?
The next earnings date of Novacyt SA(XPAR:ALNOV) is 2023-09-29 Est..
Does Novacyt SA(XPAR:ALNOV) pay dividends? If so, how much?
Novacyt SA(XPAR:ALNOV) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
